Additionally, no alterations in plasma IFN-γ, TNF-α, or IL-6 concentrations were attributed to SNS-101 at any time point or dose level, substantiating previous in vitro, ex vivo and in vivo CRS model data (Supplementary Data File 1). The gene discussed is IFNG; the disease is congenital rubella syndrome.